Doustdar frames the Wegovy pill as a must-win as Canadian generics land

Novo Nordisk chief executive Mike Doustdar described the U.S. launch of an oral version of Wegovy as the company's "must-win" battle for 2026, speaking as generic injectable semaglutide from Dr. Reddy's and Apotex reached Canadian pharmacies ^[1]. Doustdar's framing puts the pill up against two pressures at once: Eli Lilly's oral rival, orforglipron, sold under the brand name Foundayo, and generic semaglutide in markets where Novo Nordisk's patent protection has already lapsed ^[1].

The oral Wegovy pill won U.S. approval in December 2025, setting up what Novo Nordisk has called a defining 2026 competitive fight with Lilly's orforglipron ^[1]. Novo Nordisk has said the pill will account for the bulk of its 2026 growth ^[1].

In Canada, the generic threat traces back to a patent decision. Patent expert Tahir Amin of the group I-MAK told reporters that Novo Nordisk could have extended its Canadian Ozempic patent protection until 2028 but chose not to renew it ^[1]. Separate reporting on the same patent history says Novo Nordisk stopped paying a roughly $250 Canadian annual patent maintenance fee back in 2018, a lapse that ultimately opened the door for generic semaglutide to reach Canadian shelves in 2026 ^[1].

That opening is now working its way through Canada's regulatory system. As of early August, the Canadian Generic Pharmaceutical Association said more than 500 generic drug submissions of all kinds sat with Health Canada, with more than 100 backlogged, while seven generic semaglutide files specifically remained under review ^[1]. Separately, Health Canada's public drug registry listed two other generic semaglutide products, Aspen-Semaglutide and Sevmia, as approved but not yet marketed as of late July ^[1]. Canadian benefit plan sponsors were also bracing for a scheduled price mechanism: under Canada's pricing rules, a third generic entrant would trigger a 65% cut to the list price, with Sandoz targeting a third-quarter 2026 launch ^[1]. Canada's tiered pricing system sets a first generic at 75% to 85% of the brand price, dropping to 35% once three or more generics are on the market ^[1]. Sandoz has also estimated a proposed generic tirzepatide, the molecule in Mounjaro and Zepbound, would cost $200 to $400 a month ^[1].

Why it matters for patients

None of the Canadian generic approvals change what people in the United States pay today, since these are Canadian regulatory actions and the sources describe pricing mechanisms specific to Canada's public and private drug plans ^[1]. But the timing matters for U.S. patients weighing options. Doustdar's decision to call the oral Wegovy pill a must-win signals that Novo Nordisk sees its future increasingly tied to a needle-free product, at the same time Lilly is pushing its own oral option, Foundayo, in the same U.S. market ^[1]. For patients who dislike injections, that means two oral GLP-1 medicines may soon be competing for the same prescriptions. It is not stated in these sources whether semaglutide's patent protection in the United States faces a similar lapse to what happened in Canada, so any effect on U.S. generic timelines is not yet known from this reporting.

What happens next

Health Canada's seven remaining generic semaglutide files were still under review as of early August 2026, with the outcome expected to further shape Canadian pricing ^[1]. Sandoz was targeting a third-quarter 2026 launch for a competing generic, which under Canada's tiered pricing rules would trigger the deeper 65% price cut once a third generic reaches the market ^[1]. Aspen-Semaglutide and Sevmia remained approved but unmarketed as of late July, meaning their entry into Canadian pharmacies was still pending ^[1].